过氧化物酶体增殖物激活受体γ激动剂对食管鳞癌化疗敏感性影响的研究  

Effect of peroxisome proliferator-activated receptorγagonist in sensitizing cisplatin chemotherapy for esophageal squamous cell carcinoma

作　　者：吴恺[1] 何宏博 张澎 曾诚 刘东雷[1] 赵松[1] WU Kai;HE Hongbo;ZHANG Peng;ZENG Cheng;LIU Donglei;ZHAO Song(Department of Thoracic Surgery,the First Affiliated Hospital,Zhengzhou University,Zhengzhou 450052,China)

机构地区：[1]郑州大学第一附属医院胸外科,河南郑州450052

出　　处：《肿瘤基础与临床》2020年第6期461-464,共4页journal of basic and clinical oncology

基　　金：国家自然科学基金青年基金资助项目(81702971);河南省高等学校重点科研项目(18A320054);河南省科技攻关项目(182102310116);河南省青年人才托举工程项目(2020HYTP050)。

摘　　要：目的探讨过氧化物酶体增殖物激活受体γ(PPAR-γ)激动剂罗格列酮对食管鳞癌化疗敏感性的影响。方法MTT法检测罗格列酮、顺铂、罗格列酮联合顺铂两者联用对食管鳞癌EC109细胞生长的抑制作用;采用流式细胞术检测罗格列酮、顺铂、罗格列酮联合顺铂对EC109细胞细胞周期分布的影响。建立EC109细胞裸小鼠移植瘤模型,观察连续灌胃(罗格列酮、顺铂、罗格列酮联合顺铂)对小鼠肿瘤体积和抑制率的影响。结果罗格列酮可显著增强顺铂对EC109细胞的抑制作用,并呈现时间和剂量依赖性。细胞周期分布分析结果显示罗格列酮联合顺铂可使EC109细胞S期细胞显著增多。罗格列酮、顺铂、罗格列酮联合顺铂对EC109细胞裸鼠移植瘤的抑制率分别为40.21%、52.84%、75.22%,罗格列酮联合顺铂组小鼠肿瘤体积显著减小。结论PPAR-γ激动剂罗格列酮能够显著增强顺铂对食管鳞癌的化疗敏感性,其机制可能主要与S期细胞周期阻滞有关。Objective To investigate the role of rosiglitazone[peroxisome proliferator-activated receptorγ(PPAR-γ)]in the cisplatin sensitivity of esophageal squamous cell carcinoma.Methods After treatment of rosiglitazone,cisplatin or the joint of them,MTT assay was used to evaluate the cell inhibition rates of esophageal squamous cell carcinoma EC109 cells,cell cycle distribution of esophageal squamous cell carcinoma EC109 cells was detected by using flow cytometry.The heterotopic xenograft model was established by using esophageal squamous cell carcinoma EC109 cells,and the tumor volumes and inhibition rates were calculated after treated with rosiglitazone,cisplatin and rosiglitazone plus cisplatin through intragastric administration for two weeks.Results Rosiglitazone sensitized the growth inhibition to esophageal squamous cell carcinoma EC109 cells for cisplatin chemotherapy in a dose-and time-dependent manner.Cell numbers of S phase were increased after administration with rosiglitazone plus cisplatin.The tumor inhibition rates of rosiglitazone,cisplatin and rosiglitazone plus cisplatin were respectively 40.21%,52.84%and 75.22%.The tumor volume was decreased after treatment of rosiglitazone plus cisplatin.Conclusion Rosiglitazone sensitizes cisplatin chemotherapy sensitivity for esophageal squamous cell carcinoma through S cycle arrest.

关 键 词：过氧化物酶体增殖物激活受体Γ 罗格列酮 食管鳞癌 顺铂 细胞周期 

分 类 号：R735.1[医药卫生—肿瘤]